Skip to content

NADPH Oxidase Polymorphisms in Obstructive Sleep Apnea Syndrome (OSAS)

NADPH Oxidase p22phox Polymorphisms and Oxidative Stress in Patients With Obstructive Sleep Apnea

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01141829
Enrollment
Unknown
Registered
2010-06-11
Start date
Unknown
Completion date
Unknown
Last updated
2010-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oxidative Stress, Single Nucleotide Polymorphism, Sleep Apnea Syndrome

Keywords

NADPH oxidase

Brief summary

Obstructive Sleep Apnea (OSA) is associated with increased oxidative stress. The major sources of Reactive Oxygen Species (ROS) in the vasculature are the NADPH oxidases. Several polymorphisms related to NADPH oxidase expression or NADPH oxidase activity has been identified. The investigators are going to compare the distribution of the allelic frequencies of A-930G and C242T polymorphisms and their possible relationship with the levels of 8-isoprostanes as a marker of oxidative stress in patients with OSA and in a control group without OSA.

Detailed description

DESIGN: CASE-CONTROL STUDY METHODS: We are going to determine the A-930G and C242T p22phox genotypes in patients with OSA and healthy subjects recruited from sleep unit of Son Dureta University Hospital, (Palma de Mallorca, Spain). 8-Isoprostane is going to be measured as an oxidative stress marker with an 8-isoprostane EIA kit (Cayman Chemicals Company, USA) in plasma samples.

Interventions

None listed

Sponsors

Spanish Research Center for Respiratory Diseases
CollaboratorOTHER
Sociedad Española de Neumología y Cirugía Torácica
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Polyysomnografic study with Apnoea/Hypoapnoea Index higher to 10 in patients and lower in controls.

Exclusion criteria

* chronic obstructive pulmonary disease, liver cirrhosis, thyroid dysfunction, rheumatoid arthritis, chronic renal failure and/or psychiatric disorders.

Countries

Spain

Contacts

Primary ContactMónica de La Peña, MD
monica.delapena@ssib.es0034971175112

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026